Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 6/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | CCR3 | P51677 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11033727 | 0.98 | TBXAS1 (0.50) | TBXAS1GSK3BPRSS1FFAR1 | |
| SCHEMBL22120309 | 0.98 | TBXAS1 (0.50) | TBXAS1GSK3BPRSS1FFAR1 | |
| SCHEMBL30826996 | 0.98 | TBXAS1 (0.50) | TBXAS1GSK3BPRSS1FFAR1 | |
| SCHEMBL5314368 | 0.95 | TBXAS1 (0.52) | TBXAS1GSK3BPRSS1KCNA3HRH1 | |
| SCHEMBL3901418 | 0.90 | TBXAS1 (0.54) | TBXAS1GSK3BFFAR1HRH1CCR3 | |
| SCHEMBL7388461 | 0.90 | TBXAS1 (0.56) | TBXAS1PRSS1KCNA3HRH1CCR3 | |
| SCHEMBL690259 | 0.85 | TBXAS1 (0.52) | TBXAS1PRSS1FFAR1KCNA3HRH1 | |
| SCHEMBL28380411 | 0.83 | TBXAS1 (0.51) | TBXAS1PRSS1FFAR1KCNA3HRH1 | |
| SCHEMBL10289405 | 0.83 | TSHR (0.57) | TBXAS1 | |
| SCHEMBL688706 | 0.83 | TBXAS1 (0.54) | TBXAS1PRSS1KCNA3HRH1CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110981768-A | Simple synthesis method of aryl difluoroalkyl sulfoxide compound | 山东理工大学 | 2020-04-10 | — | — | CN | disclosed |
| US-20080312286-A1 | Indanone Potentiators of Metabotropic Glutamate Receptors | MERCK SHARP & DOHME CORP. | 2008-12-18 | — | — | US | disclosed |
| CN-1993335-A | Indanone potentiators of metabotropic glutamate receptors | MERCK & CO INC (US) | 2007-07-04 | — | — | CN | disclosed |
| EP-1773792-A1 | INDANONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Merck & Co., Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006015158-A1 | INDANONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| US-6992085-B2 | Octahydro-2H-pyrido[1,2-a]pyrazine compounds | LES LABORATORIES SERVIER (FR) | 2006-01-31 | — | — | US | disclosed |
| US-20050288346-A1 | Acetophenone potentiators of metabotropic glutamate receptors | MERCK & CO., INC. | 2005-12-29 | — | — | US | disclosed |
| EP-1556038-A2 | ACETOPHENONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Merck & Co., Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| CN-1197863-C | NOvel octahydro-2H-pyridino-[1,2-a] pyrazine compound, its prepn. process and medicinal compound contg. them | SERVIER LAB (FR) | 2005-04-20 | — | — | CN | disclosed |
| WO-2004018386-A2 | ACETOPHENONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK & CO., INC. (US) | 2004-03-04 | — | — | WO | disclosed |
| EP-1275647-B1 | Octahydro-2H-pyrido[1,2-a]pyrazine derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2003-11-12 | — | — | EP | disclosed |
| US-20030195216-A1 | Octahydro-2H-pyrido[1,2-a] pyrazine compounds | LES LABORATOIRES SERVIER (FR) | 2003-10-16 | — | — | US | disclosed |
| CN-1397557-A | NOvel octahydro-2H-pyridino-[1,2-a] pyrazine compound, its prepn. process and medicinal compound contg. them | SAVOIREN LAB (FR) | 2003-02-19 | — | — | CN | disclosed |
| EP-1275647-A1 | Octahydro-2H-pyrido[1,2-a]pyrazine derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2003-01-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312286-A1 | Indanone Potentiators of Metabotropic Glutamate Receptors | GRM2, GRIK2, GRM1 | TBXAS1 2627/4885GSK3B 2789/4885PRSS1 4177/4885 |
| US-20050288346-A1 | Acetophenone potentiators of metabotropic glutamate receptors | GRM2, GRM1, GRIK2 | TBXAS1 2736/4885GSK3B 3476/4885PRSS1 3891/4885 |
| US-20030195216-A1 | Octahydro-2H-pyrido[1,2-a] pyrazine compounds | CYP2W1, OXER1, IL1R1 | TBXAS1 620/4885GSK3B 1935/4885PRSS1 3863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.